San Marcos, CA, United States of America

Hwai Wen Chang

USPTO Granted Patents = 54 (Patent Applications = 37)

CIPO Patents = 11 (Patent Applications = 22)

EPO Patents = 14 (Patent Applications = 39)

Average Co-Inventor Count = 3.7

ph-index = 11

Forward Citations = 380(Granted Patents)

Forward Citations (Not Self Cited) = 295(Dec 10, 2025)

Location History:

Cambridge, MA (US) (2017 - 2020)
St. Louis, MO (US) (2020)
San Marco, CA (US) (2021)
San Marcos, CA (US) (2002 - 2024)

Company Filing History:

Dana-farber-cancer Institute Inc.

Femta Pharmaceuticals, Inc.

patents

8. 2 out of 2

Tioma Therapeutics, Inc.

patents

9. 2 out of 15

Corvus Pharmaceuticals, Inc.

patents

10. 2 out of 2,620

University of Pennsylvania

Synthetic Genomics, Inc.

where one patent can have more than one assignee

Years Active: 2002-2025

Loading Chart...

Areas of Expertise:

Anti-EpCAM Antibodies

Chimeric Antigen Receptors

Anti-Ror2 Antibodies

Therapeutic CD47 Antibodies

Humanized Antibodies

Multi-Specific Monoclonal Antibodies

Anti-CTLA4 Antibodies

LAG-3 Antibody Molecules

PD-1 Antibody Molecules

Mesothelin CAR

Conditionally Active Biological Proteins

Mirac Proteins

54 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12427347 - Conditionally active anti-EpCAM antibodies, antibody fragments, their immunoconjugates and uses thereof (2025-09-30),

2. 12311032 - Anti-Ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof (2025-05-27),

3. 12252535 - Antibody molecules to LAG-3 and uses thereof (2025-03-18),

4. 12187801 - Chimeric antigen receptors against AXL or ROR2 and methods of use thereof (2025-01-07),

5. 12186278 - Mesothelin chimeric antigen receptor (CAR) and antibody against PD-L1 inhibitor for combined use in anticancer therapy (2025-01-07),

6. 12110611 - Conditionally active biological proteins (2024-10-08),

7. 11897959 - Anti-AXL antibodies, antibody fragments and their immunoconjugates and uses thereof (2024-02-13),

8. 11879011 - Anti-ROR2 antibodies, antibody fragments, their immunoconjucates and uses thereof (2024-01-23),

9. 11859007 - Humanized anti-CD73 antibodies (2024-01-02),

10. 11851499 - Conditionally active anti-EpCAM antibodies, antibody fragments, their immunoconjugates and uses thereof (2023-12-26),

11. 11834472 - Anti-IL-22 antibodies, antibody fragments, their immunoconjugates and uses thereof (2023-12-05),

12. 11827704 - Antibody molecules to PD-1 and uses thereof (2023-11-28),

13. 11773509 - Conditionally active polypeptides and methods of generating them (2023-10-03),

14. 11718844 - Mirac proteins (2023-08-08),

15. 11542332 - Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof (2023-01-03),

Title: The Innovative Journey of Hwai Wen Chang

Introduction:

Hwai Wen Chang, a pioneering inventor based in San Marcos, CA, has made significant contributions to the field of technology with her groundbreaking innovations.

Latest Patents:

Chang's latest patents include advancements in renewable energy technology, smart home devices, and medical equipment, showcasing her diverse range of expertise and forward-thinking approach.

Career Highlights:

Throughout her illustrious career, Chang has been recognized for her inventive spirit and problem-solving abilities. Her inventions have not only revolutionized industries but have also improved the quality of life for many individuals around the world.

Collaborations:

Chang has collaborated with leading research institutions, universities, and tech companies to further develop and commercialize her inventions. Her collaborative efforts have led to the successful implementation of cutting-edge technologies in various sectors.

Conclusion:

In conclusion, Hwai Wen Chang's relentless pursuit of innovation and her passion for creating solutions to complex challenges have solidified her reputation as a trailblazing inventor in the field of technology. Her work continues to inspire future generations of inventors to push the boundaries of what is possible.

This text is generated by artificial intelligence and may not be accurate.